Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by T. Harrer
Early Onset of Autoimmune Disease by the Retroviral Integrase Inhibitor Raltegravir
Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
Related publications
Evidence That Raltegravir (Isentress, Merck), a Retroviral Integrase Inhibitor Is Effective Against Recurrent Human Herpes Simplex Virus Infection Associated With NK-cell Deficiency
Pediatrics & Therapeutics
Mutations Associated With Failure of Raltegravir Treatment Affect Integrase Sensitivity to the Inhibitor in Vitro
Antimicrobial Agents and Chemotherapy
Infectious Diseases
Pharmacology
Raltegravir: A Potent and Safe Integrase Inhibitor With a Favourable Impact on Cardiovascular and Liver Profile
Journal of the International AIDS Society
Environmental
Public Health
Infectious Diseases
Occupational Health
A Long-Acting Formulation of the Integrase Inhibitor Raltegravir Protects Humanized BLT Mice From Repeated High-Dose Vaginal HIV Challenges
Journal of Antimicrobial Chemotherapy
Infectious Diseases
Microbiology
Pharmacology
Retroviral Integrase Structure and DNA Recombination Mechanism
Early-Onset Alzheimer Disease
Neurologic Clinics
Neurology
Early Onset Alzheimer's Disease
MOJ Gerontology & Geriatrics
Early-Onset Lafora Body Disease
Figure 1: FDA Approved Integrase Strand Transfer Inhibitors INSTIs: Raltegravir, Elvitegravir and Dolutegravir.
